The AYA WELL study is a 2-arm randomized clinical trial to test the efficacy of a theory-based, mHealth weight management intervention adapted specifically for adolescent and young adult cancer survivors compared to a self-guided arm. Participants, diagnosed with cancer between ages 15-39, currently age 18-39, post-treatment at least 6 months, and who have overweight or obesity will be randomized to receive either: 1) a comprehensive mHealth weight management program (intervention) or 2) digital tools + health education + peer support (self-guided) over 12 months. Outcomes will be assessed at 3, 6, and 12 months.
18-39 years old at the time of consent.
Diagnosed with first invasive cancer between ages 15-39 years (self-report).
Within 10 years of diagnosis with no evidence of progressive disease or second primary cancers (self-report).
Completed active cancer directed therapy (cytotoxic chemotherapy, radiation therapy and/or definitive surgical intervention) at least six months prior to enrollment; may be receiving "maintenance" therapy to prevent recurrences (self-report).
Type 1 diabetes or currently receiving certain medical treatments for Type 2 diabetes
Report a history of heart attack or stroke within previous 6 months
Health problems which preclude ability to walk for physical activity (e.g., lower limb amputation). Participants endorsing items 1-4 on the Physical Activity Readiness Questionnaire (PAR-Q) (experience of heart problems, frequent chest pains, or faintness or dizziness) will be excluded from the study.
Lost 5% or more of body weight (and kept it off) in the last 3 months
UNC Lineberger Comprehensive Cancer Center
Lead sponsor
Virginia Commonwealth University
Collaborator
National Cancer Institute (NCI)
Collaborator